Opinion|Videos|November 8, 2024
CAR T-cell Therapies for Multiple Myeloma: KarMMa-3 and CARTITUDE-4 Study Updates at IMS 2024
Panelists discuss how the KARMMA-3 study’s design, patient population, and efficacy outcomes—including overall survival data—inform the approval of ide-cel, as well as the implications of CARTITUDE-4’s recent findings on treatment selection and approaches for cilta-cel in chimeric antigen receptor T-cell therapy.
Advertisement
Episodes in this series
- Dr Ajai Chari to Dr Martin: Let’s dive deeper into the KARMMA-3 study that got ide-cel approved. Dr Martin: Can you please review the KARMMA-3 study design, patient population, and efficacy outcomes including overall survival (OS) data?
Resource Link:
Ailawadhi S et al. KarMMa-3 Updated Analysis 2024 - online ahead of print Rodriguez-Otero P et al. KARMMA-3 NEJM 2023 Idel-cel rrMM. Rodiguez-Otero P et al. KarMMa-3 Updated Analysis. ASH 2023 Oral Abstract.
- Dr Ajai Chari to Dr Callander: Now that we have discussed KARMMA-3, let’s review CARTITUDE-4. Dr Callander: Can you please review the CARTITUDE-4 study design, patient population, and recently presented IMS 2024 CARTITUDE-4 OS data updates
Resource Link
OA-65 IMS 2024 CARTITUDE 4 or (see page 14)
Advertisement
Related to this article
Robert A. Winn, MD, discussed his path to becoming a physician, scientist, and leader at Fox Chase Cancer Center.
Updated analyses from a phase 2a study suggest durable survival with namodenosen in a subset of heavily pretreated patients with advanced PDAC.
Need a refresh on the current regulatory landscape for GI oncology? We've got you covered. Here's everything that moved the needle across GI malignancies this month.
Toni Choueiri, MD, discusses the clinical significance of the FDA approval of adjuvant belzutifan plus pembrolizumab in ccRCC.
Panelists discuss how nodal burden, NGS turnaround time, and regional resource heterogeneity shape treatment sequencing in EGFR-mutated NSCLC in Latin America.
Zanubrutinib plus R-BAP produced responses in both younger and older patients with previously untreated mantle cell lymphoma.
Breast oncologists weigh the future role of radiographic progression vs liquid biopsy in the timing of therapeutic shifts in metastatic breast cancer.
Sylvester cancer researchers became wildland firefighters themselves to study, from the inside, cancer risks tied to the job.
Advertisement
Advertisement
Trending on OncLive
1
SERENA-6 Controversies Push the Breast Cancer Field to Consider the Future Role of ctDNA-Guided Treatment Decisions
2
FDA Approval Positions Belzutifan Plus Pembrolizumab as a New Adjuvant Standard in ccRCC
3
SYNC-T SV-102 Employs Novel Mechanism to Target Immunologically ‘Cold’ Tumors in Advanced Metastatic Prostate Cancer
4
Surgeons, Medical Oncologists, and Radiation Oncologists Debate Current Thresholds for Systemic Therapy in EGFR-Mutated NSCLC
5